相关实验视频

Updated: Feb 19, 2026

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis

Published on: August 15, 2025

迪奥斯皮罗斯卡基叶的多烯酸提取物作为一种新的食用抗糖剂来源:生物可访问性和结构-活性关系调查

Giulia Moretto¹, Raffaella Colombo², Sara Perteghella²

¹Drug Sciences Department, University of Pavia, 27100 Pavia, Italy; National Biodiversity Future Center (NBFC), 90133 Palermo, Italy.

Food research international (Ottawa, Ont.)

|February 18, 2026

概括

迪奥斯皮罗斯叶提取物通过捕获有害化合物和抑制先进的糖化末端产物 (AGEs) 来显示抗糖化和抗衰老潜力. 然而,低生物可访问性需要载体,以便有效地作为食品补充剂使用.

科学领域:

食品科学食品科学食品科学
生物化学生物化学
药理学药理学是指药理学的学科.

背景情况:

Diospyros kaki (日本) 是意大利生物多样性的一部分,其叶子被认为具有潜在的补充食品应用.
首次研究了D. kaki多基提取物的抗糖和抗衰老特性.
糖化,一个与衰老和慢性疾病相关的过程,涉及到高级糖化最终产品 (AGEs) 的形成.

研究的目的:

评估D. kaki多基提取物的抗糖和抗衰老潜力.
研究已识别的化合物与AGE受体 (RAGE) 的相互作用.
评估提取物对潜在的食品成分应用的生物可访问性和Caco-2细胞透性.

主要方法:

在体外模型系统模拟糖化反应步骤.
RP-HPLC-DAD-ESI-MS/MS用于化合物的表征.
分子建模以研究化合物-RAGE相互作用.
在体外Infogest消化方案与Caco-2细胞测定用于生物可访问性和透性相结合.

主要成果:

提取物有效地捕获了二碳化合物,并抑制了中间和最终AGE的形成 (高达93%).
十三种化合物,主要是kaempferol-3-O-glucoside,通过分子建模证明了与RAGE V域的结合亲和力.
生物可访问性是有限的 (关键糖化物口服<40%,肠道5%),在Caco-2细胞中没有检测到代谢物,表明透性差.

结论:

迪奥斯皮洛斯卡基多基提取物在体外表现出显著的抗糖和抗衰老特性.
已确定的多与RAGE相互作用,表明抗衰老作用的机制.
低的多生物可访问性和透性凸显了稳定策略的需要,例如合适的载体,以有效地作为食品成分使用.

关键词:

与衰老相关的疾病.抗糖药剂是一种抗糖药剂.生物可访问性生物可访问性可食用的植物提取物.意大利的生物多样性.分子对接是分子对接.在RAGE受体中,RAGE受体是

更多相关视频

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria

Published on: February 28, 2025

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...